Resources designed to educate your practice
Forms
Test requisition form
Complete this form and fax or email it to us to order an Oncodetect MRD test today. You can also quickly complete this form online in our
General resources
Next-generation Oncodetect test overview
Learn about the fundamentals of the next-generation Oncodetect MRD test, including its design, performance, and workflow.
Oncodetect MAESTRO technology overview
Learn about how the next-generation Oncodetect MRD test is powered by MAESTRO technology to drive highly sensitive detection of ultra-low levels of ctDNA.
Oncodetect test version comparison
Explore how the next-generation Oncodetect MRD test has evolved and how it compares to our first-generation MRD test.
Oncodetect early-stage TNBC data
Explore findings from the B-59 study demonstrating prognostic value following surgery in patients with early-stage triple negative breast cancer.
Videos
Specimen instructions
Tumor tissue specimen instructions
Pathology specimen requirements and delivery instructions for tumor tissue samples.
Blood specimen instructions
Phlebotomy and delivery instructions for the clinical lab.
Managed blood draw services
Information on how we manage blood draw services using phlebotomy partners.
Managed blood draw services - quick facts
Our at-a-glance performance metrics and blood draw services.
New developments
Exact Sciences announces expanded clinical validation of the Oncodetect test and molecular residual disease innovation roadmap
The Beta-CORRECT study confirms the clinical utility of the Oncodetect test for recurrence monitoring in stage II, III and resectable stage IV colorectal cancer; a whole-genome Oncodetect test powered by MAESTRO with an ultra-low limit of detection will be introduced in 2026.
Evidence validates the Oncodetect test’s ability to predict recurrence
Results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, show a positive Oncodetect test result is strongly associated with recurrence in stage III colon cancer patients.
Current MRD clinical studies
By investing in robust research and building a strong network of clinical collaborations, we are committed to making MRD testing an essential tool in cancer care.
Case studies and sample reports
Surveillance of a patient with stage IIA HR+ breast cancer
- Diagnosis: Stage IIA HR+/HER2-negative breast cancer, BRCA2 and ESR1 mutations
- Surgical intervention: Lumpectomy
- Post-operative findings: Positive circulating tumor DNA (ctDNA)
Surveillance of a patient with Triple Negative Breast Cancer (TNBC)
A 45-year old pre-menopausal woman with no comorbidities was diagnosed with stage III triple negative breast cancer (TNBC) and received multiple tests including the Riskguard, OncoExTra, and Oncodetect MRD tests.
- Diagnosis: Stage III TNBC, negative germline testing, MSI-H/MMR deficiency
- Surgical intervention: Resection of primary tumor
- Post-operative findings: Positive circulating tumor DNA (ctDNA)
